Clinical trial · Interventional
Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse
National, Randomized, Phase II Study Comparing Efficacy of Weekly Administration of Paclitaxel in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse
NCT00189566CI-TRIAL-00004467completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will look at the efficacy and safety of weekly administration of paclitaxel (Taxol®) in monotherapy compared to paclitaxel in combination with topotecan or carboplatin in patients with ovarian cancer in early relapse.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fallopian Tube Cancer | Malignant Fallopian Tube Neoplasm | ALIAS | 0.90 |
| Malignant Tumor of Peritoneum | — | UNRESOLVED | — |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carboplatin | Drug | Carboplatin | ALIAS |
| Paclitaxel | Drug | Paclitaxel | ALIAS |
| Topotecan | Drug | Topotecan | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Progression-free survival of patients in the three groups
Secondary outcomes (4)
- measure
- Overall survival
- measure
- Rate of response and rate of progression at the end of treatment
- measure
- Qualitative and quantitative toxicities
- measure
- Quality of life
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged \> 18 * Histologically proven diagnosis of cancer of the ovary, the fallopian tube or peritoneum * Peritoneal and/or nodes and/or visceral metastases * Disease in progression under treatment or within 6 months after a first or second platinum-based line * A period of 3 weeks between last chemotherapy and inclusion * Measurable disease (Response Evaluation Criteria in Solid Tumors \[RECIST\] criteria) or cancer antigen (CA) 125 assessable disease (Gynecologic Cancer Intergroup \[GCIG\] criteria) * ECOG performance status \< 2 * Life expectancy of at least 12 weeks Exclusion Criteria: * Previously received weekly administration of paclitaxel chemotherapy * Involved in a trial within the last 30 days * Previously received a bone marrow autogreffe or irradiation of the abdomen within 5 years, due to intensive chemotherapy * Prior diagnosis of malignancy * History of ischemic cardiopathy, congestive heart failure (New York Heart Association \[NYHA\] \> 2), arrhythmia, hypertension, or significant valvulopathy * Pre-existing motor or sensory neurologic pathology or symptoms National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) grade \> 2 * Bone marrow, renal, or hepatic insufficiency * Severe active infection or occlusive or sub-occlusive disease * History of symptomatic brain metastases * Fertile women not using adequate contraceptive methods * Pregnant or breast feeding women * Hypersensitivity to compounds chemically related to paclitaxel, topotecan, or carboplatin
References
Publications (0)
Data not yet available
No reference posted for this study.